The mechanism difference: GLP-1 only versus dual GIP and GLP-1
Both agents mimic gut-derived hormones called incretins that are released after eating. GLP-1 (glucagon-like peptide-1) stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and acts on appetite centers in the hypothalamus. Semaglutide is a GLP-1 receptor agonist: it activates that one receptor.
Tirzepatide is a dual agonist. It activates GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP is the other major incretin hormone, and GIP receptor activation adds effects on insulin sensitivity and fat metabolism that GLP-1 alone does not produce. The precise contribution of the GIP pathway to weight loss is still being characterized, but the trial results show the dual mechanism translates to meaningfully greater average weight reduction.
Both are taken as a once-weekly subcutaneous injection and are started at a low dose that a clinician increases over several weeks. That titration is what keeps side effects manageable, and it is one reason the medication is prescribed and monitored rather than sold over the counter.
Head-to-head evidence: SURPASS-2
SURPASS-2 is the trial that matters most here because it randomized participants to tirzepatide or semaglutide directly, rather than comparing each to placebo. It enrolled 1,879 adults with type 2 diabetes and compared tirzepatide at 5 mg, 10 mg and 15 mg weekly against semaglutide 1 mg weekly over 40 weeks.
- Body weight: mean loss of 7.8 kg, 10.3 kg and 12.4 kg on tirzepatide 5, 10 and 15 mg, against 6.2 kg on semaglutide 1 mg. The 10 mg and 15 mg doses were statistically superior.
- HbA1c: reductions of 2.01%, 2.24% and 2.30% on the three tirzepatide doses, against 1.86% on semaglutide 1 mg.
- Glycemic target: a higher share of tirzepatide participants reached HbA1c below 7.0% at every dose.
The important caveat: the comparator was semaglutide 1 mg, a diabetes dose, not the 2.4 mg dose used for weight management. A randomized head-to-head of tirzepatide against semaglutide 2.4 mg in people without diabetes had not been published as of this writing. The direction of the signal is consistent; the size of the gap at the weight-management dose is not something SURPASS-2 can tell you.
SURPASS-2 is the rare direct comparison, and at every dose the dual-incretin agent moved the scale further than GLP-1 alone.
Weight management trials: STEP 1 and SURMOUNT-1
For weight management without type 2 diabetes, the evidence comes from two separate trials that were not designed to be compared with each other.
- STEP 1 (semaglutide 2.4 mg): 1,961 adults with obesity or overweight plus a weight-related condition. Mean weight loss of about 14.9% of body weight at 68 weeks, against 2.4% on placebo.
- SURMOUNT-1 (tirzepatide 5, 10, 15 mg): 2,539 adults with obesity or overweight plus a comorbidity. Mean weight loss of about 15.0%, 19.5% and 20.9% at 72 weeks, against 3.1% on placebo. At the highest dose, 37% of participants lost 25% or more of their body weight.
| Metric | Semaglutide 2.4 mg (STEP 1, 68 weeks) | Tirzepatide 15 mg (SURMOUNT-1, 72 weeks) |
|---|---|---|
| Receptor targets | GLP-1 only | GIP + GLP-1 (dual) |
| Average weight loss | About 14.9% of body weight | About 20.9% of body weight |
| Lost 25% or more | Not reported at that threshold | 37% of participants |
| Trial population | Obesity or overweight, no type 2 diabetes | Obesity or overweight, no type 2 diabetes |
Separate trials with different designs and durations, not a head-to-head. The gap at comparable doses is large enough to reflect a real pharmacological difference, and individual results vary widely in both.
Side effects: the same profile, individual tolerability
Both agents share the GLP-1-mediated GI profile. Nausea, diarrhea, vomiting and constipation are the most common events, most prominent during dose escalation, and they ease substantially once a stable dose is reached. In SURPASS-2 the GI event rates were broadly similar, with slightly more nausea at the higher tirzepatide doses.
Both carry the same class warning about thyroid C-cell tumors seen in rodent studies, with unknown relevance to humans, and both are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2. Tolerability is genuinely individual: some people tolerate one agent much better than the other, and that is a legitimate clinical reason to choose between them even where the efficacy data favors tirzepatide at the population level.
How a clinician decides between them
Trial averages describe populations. Some STEP participants on semaglutide lost more than the average SURMOUNT participant on tirzepatide, and some on tirzepatide had modest responses. Predicting which agent an individual will respond to better is not currently possible, so the decision rests on the factors a clinician can see:
- Weight loss goal and timeline: for a higher target, the greater average efficacy of tirzepatide at the upper doses can be clinically meaningful.
- Prior medication history: someone who has used semaglutide with an inadequate response or tolerability problems may be a candidate for tirzepatide, and the reverse also applies. Someone doing well on semaglutide has a reason to stay on it.
- Cardiovascular risk profile: semaglutide has established cardiovascular outcome data (SUSTAIN-6, LEADER) that tirzepatide is still accumulating in long-term follow-up. For someone with existing cardiovascular disease, that can influence the recommendation.
- Comorbidities and interactions: renal function, current medications and history with prior weight management approaches all enter the picture and are not captured in trial averages.
Safety, sourcing and brand names
The compounded semaglutide and tirzepatide PepScribe offers are not FDA-approved. They are prepared by licensed 503A pharmacies in the USA under a separate regulatory pathway. No hidden overseas supply chain.
This comparison discusses semaglutide and tirzepatide as the active ingredients that are prescribed and compounded. Branded names refer to specific FDA-approved manufactured products that are distinct from compounded preparations. Nothing on this page implies a compounded preparation is equivalent to any branded drug.
Neither medication should be obtained from unregulated online sources, research chemical suppliers or gray-market vendors, where purity, sterility and dosing cannot be verified. Results vary from person to person, and neither medication is a guarantee of any outcome. This page is educational information, not medical advice.
How PepScribe handles both
You do not have to decide between them on your own. The free assessment routes your answers to a licensed clinician, who recommends the option that fits your history and goals, or neither, if that is the right call. You are not charged for medication unless it is prescribed.
Common questions
Is tirzepatide better than semaglutide for weight loss?
In the SURPASS-2 head-to-head trial, tirzepatide produced greater weight loss than semaglutide 1 mg at every dose studied, up to roughly 6 kg more over 40 weeks. Trial averages describe populations, not people. Whether that difference matters for you is a clinical judgment your clinician makes against your history, tolerability and goals.
What is the main difference between tirzepatide and semaglutide?
Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GIP and GLP-1 receptor agonist. The second pathway is the main mechanistic difference, and it is the pharmacological reason tirzepatide reached larger average weight loss in the trials.
Do tirzepatide and semaglutide have the same side effects?
They overlap heavily because both activate the GLP-1 receptor. Nausea, diarrhea, vomiting and constipation are the most common for both, mostly during dose increases. Both carry the same thyroid C-cell class warning. Some people tolerate one better than the other, and that is a legitimate reason for a clinician to choose between them.
Can I switch between them?
Only under clinician guidance. Switching changes the receptor activity and the titration schedule, so the timing and the starting dose on the new medication are clinical decisions rather than a self-serve swap.
What is the regulatory status of compounded semaglutide and tirzepatide?
No. Brand-name semaglutide (Ozempic, Wegovy) and brand-name tirzepatide (Mounjaro, Zepbound) are FDA-approved. The compounded versions PepScribe offers are not FDA-approved. They are prepared by licensed 503A pharmacies in the USA under a separate regulatory pathway, when a clinician determines it is appropriate.
How do I know which one is right for me?
Start with the free assessment. A licensed clinician reviews your goals, medical history, current medications and eligibility, then recommends the option that fits, or neither. You are not charged for medication unless it is prescribed.
